| Title : Oximes as pretreatment before acute exposure to paraoxon - Lorke_2019_J.Appl.Toxicol_39_1506 |
| Author(s) : Lorke DE , Nurulain SM , Hasan MY , Kuca K , Petroianu GA |
| Ref : J Appl Toxicol , 39 :1506 , 2019 |
| Abstract : Organophosphates, useful agents as pesticides, also represent a serious danger due to their high acute toxicity. There is indication that oximes, when administered before organophosphate exposure, can protect from these toxic effects. We have tested at equitoxic dosage (25% of LD01 ) the prophylactic efficacy of five experimental (K-48, K-53, K-74, K-75, K-203) and two established oximes (pralidoxime and obidoxime) to protect from mortality induced by the organophosphate paraoxon. Mortalities were quantified by Cox analysis and compared with those observed after pretreatment with a strong acetylcholinesterase inhibitor (10-methylacridine) and after the FDA-approved pretreatment compound pyridostigmine. All nine tested substances statistically significantly reduced paraoxon-induced mortality. Best protection was conferred by the experimental oxime K-48, reducing the relative risk of death (RR) to 0.10, which was statistically significantly superior to pyridostigmine (RR = 0.31). The other oximes reduced the RR to 0.13 (obidoxime), 0.20 (K-203), 0.21 (K-74), 0.24 (K-75) and 0.26 (pralidoxime), which were significantly more efficacious than 10-methylacridine (RR = 0.65). These data support the hypothesis that protective efficacy is not primarily due to cholinesterase inhibition and indicate that the tested experimental oximes may be considered promising alternatives to the established pretreatment compound pyridostigmine. |
| ESTHER : Lorke_2019_J.Appl.Toxicol_39_1506 |
| PubMedSearch : Lorke_2019_J.Appl.Toxicol_39_1506 |
| PubMedID: 31264735 |
Lorke DE, Nurulain SM, Hasan MY, Kuca K, Petroianu GA (2019)
Oximes as pretreatment before acute exposure to paraoxon
J Appl Toxicol
39 :1506
Lorke DE, Nurulain SM, Hasan MY, Kuca K, Petroianu GA (2019)
J Appl Toxicol
39 :1506